Jump to main content
US EPA
United States Environmental Protection Agency
Search
Search
Main menu
Environmental Topics
Laws & Regulations
About EPA
Health & Environmental Research Online (HERO)
Contact Us
Print
Feedback
Export to File
Search:
This record has one attached file:
Add More Files
Attach File(s):
Display Name for File*:
Save
Citation
Tags
HERO ID
2581653
Reference Type
Journal Article
Title
Indacaterol once-daily is equally effective dosed in the evening or morning in COPD
Author(s)
Magnussen, H; Verkindre, C; Jack, D; Jadayel, D; Henley, M; Woessner, R; Higgins, M; Kramer, B; INPUT study investigators
Year
2010
Is Peer Reviewed?
1
Journal
Respiratory Medicine
ISSN:
0954-6111
EISSN:
1532-3064
Volume
104
Issue
12
Page Numbers
1869-1876
Language
English
PMID
20850959
DOI
10.1016/j.rmed.2010.08.010
Web of Science Id
WOS:000284812900017
Abstract
UNLABELLED:
Indacaterol is a novel, inhaled, long-acting β(2)-agonist providing 24-h bronchodilation with once-daily (o.d.) dosing in patients with COPD. In this double-blind, incomplete block crossover study, patients with moderate-to-severe COPD were randomised to receive three treatment cycles from: indacaterol 300 μg o.d. dosed PM or AM, salmeterol 50 μg twice daily or placebo, each for 14 days. Trough FEV(1) was measured 24 h after indacaterol, and 12 h after salmeterol. Ninety-six patients (mean age: 64 years; post-bronchodilator FEV(1) 57% predicted, FEV(1)/FVC 55%) were randomised; 83 completed. After 14 days, the difference vs. placebo in trough FEV(1) for PM indacaterol was 200 mL (p < 0.001 [primary analysis]) and for AM indacaterol was 200 mL (p < 0.001). Compared with salmeterol, trough FEV(1) for PM indacaterol was 110 mL higher (p < 0.001), and for AM indacaterol was 50 mL higher (p = NS). Over 14 days, vs. placebo, both PM and AM indacaterol improved the % of nights with no awakenings (by 11.9 and 8.1 points; p < 0.01); the % of days with no daytime symptoms (by 6.7 and 5.5 points; p < 0.05); and the % of days able to perform usual activities (by 6.7 and 7.8 points; p < 0.05). Indacaterol provided 24-h bronchodilation and improvement in symptoms regardless of whether taken regularly in the morning or evening.
CLINICAL TRIAL REGISTRATION:
ClinicalTrials.gov NCT00615030.
Keywords
Chronic obstructive pulmonary disease; Evening dose; Indacaterol; Morning dose; Salmeterol
Home
Learn about HERO
Using HERO
Search HERO
Projects in HERO
Risk Assessment
Transparency & Integrity